GlassScriptPhysician profile
Allyson Catherine Bloom
NPI 1558030445
$6,065.11
in general payments reported to CMS, 2019-2025
39 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,752 · 2024: $2,430 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,775 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,775.17 |
| Education | $289.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.53 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $637.16 | 2023-2025 | Veozah |
| Abbvie INC. | $571.83 | 2023-2025 | |
| Amgen INC. | $504.52 | 2023-2025 | Evenity, Repatha, Krystexxa |
| Lilly USA, LLC | $482.89 | 2023-2025 | Mounjaro, Jardiance, Emgality |
| Inspire Medical Systems, INC. | $275.40 | 2023-2025 | Inspire |
| Pfizer INC. | $274.79 | 2023-2025 | |
| Glaxosmithkline, LLC. | $222.77 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $219.96 | 2023-2025 | Rexulti, Abilify Maintena |
| Sumitomo Pharma America, INC. | $207.40 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $203.44 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.27 | 2023-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $175.85 | 2024-2025 | Spravato |
| Axsome Therapeutics, INC. | $147.20 | 2024-2025 | Auvelity, Sunosi |
| Shield Therapeutics INC | $123.41 | 2023-2025 | Accrufer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $123.31 | 2023-2025 | |
| Exact Sciences Corporation | $95.22 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $86.58 | 2023-2024 | |
| Neos Therapeutics, LP | $83.02 | 2023-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $73.46 | 2025 | Rexulti |
| Verity Pharmaceuticals INC. | $68.20 | 2024-2025 | Tlando |
| Dexcom, INC. | $63.19 | 2023-2024 | Dexcom G6 Transmitter |
| Tris Pharma INC | $54.41 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $53.90 | 2023-2024 | Xelstrym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.76 | 2023-2024 | Synjardy, Jardiance, Tradjenta |
| Scilex Pharmaceuticals INC. | $42.53 | 2024 | |
| Idorsia Pharmaceuticals US INC | $40.20 | 2023-2024 | Quviviq |
| Phathom Pharmaceuticals, INC. | $39.87 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $38.14 | 2023-2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $35.45 | 2023 | Gvoke Hypopen |
| Corium, LLC | $23.41 | 2025 | Azstarys |
| Bausch Health US, LLC | $23.14 | 2024 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $22.69 | 2024 | Trintellix |
| Azurity Pharmaceuticals, INC. | $22.03 | 2024 | Edarbyclor |
| Ibsa Pharma INC. | $18.06 | 2023 | Tirosint, Licart |
| Optinose US, INC. | $17.64 | 2024 | |
| Antares Pharma, INC. | $15.17 | 2024 | Xyosted |
| Paratek Pharmaceuticals, INC. | $14.22 | 2023 | Nuzyra |
| Currax Pharmaceuticals LLC | $13.09 | 2023 | Nexlizet, Contrave, Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.